Posters

Low vault posterior chamber collagen copolymer phakic intraocular lenses to correct myopia: three year follow-up

Poster Details

First Author: S.Mosavi IRAN

Co Author(s):    K. Jadidi   F. Nejat                 

Abstract Details

Purpose:

To evaluate the long-term safety and efficacy of low vault posterior chamber collagen copolymer phakic intraocular lens (pIOL) implantation to correct myopia.

Setting:

Vision Health Research Center, Tehran, Iran

Methods:

Of the total 311 patients underwent pIOL implantation, 12 eyes out of 10 cases with low vault ( �â�‰�¤150�Â�µ) were enrolled in this study. Uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA), pIOL vault, endothelial cell loss, and adverse events were evaluated for 3 years after implantation of the Visian Implantable Collamer Lens pIOL for moderate to high myopia.

Results:

The mean spherical equivalent (12 eyes) decreased from -8.19 �Â�± 2.69preoperatively to -0.85�Â�±0.68 diopters, 3 years postoperatively.In term of visual outcomes, the mean UDVA ( LogMAR ) improved significantly from 1.13 �Â�±027 to 0.31 �Â�± 0.34 and mean CDVA improved (from 0.08 �Â�± 0.09 to 0.06 �Â�± 0.08) (P<0.05). The mean safety and efficacy indices were 1.039 and 0.706, respectively. No eye lost more than 2 lines of visual acuity; 82% Achieved 0.80 or better CDVA. The total endothelial cell loss (consider cumulatively at consecutive intervals through 3 years) was 9.7 %. No vision-threatening complications occurred.

Conclusions:

Implantation of the low vault collagen copolymer pIOL for moderate to high myopia was safe and effective and provided long-term predictable, stable refractive

Financial Disclosure:

NONE